Sign up now and fund within 24h to get free NKE, GPRO or DBX stock. T&Cs apply.
Redeem Now

Harmony Biosciences Holdings Inc

1 day chart

Kickstart your portfolio with a U.S. stock on us

Sign up and fund a new Wall St account and get a full share randomly chosen between GoPro, Dropbox or Nike.

Sign up and fund a new Wall St account and get a full U.S. share.

T&Cs apply
Claim now
Kickstart your portfolio with a U.S. stock on us

About HRMY

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

Buy US stocks in Australia starting with HRMY. Open an account and start investing today!

Market Capitalisation

$1.84B

Price-earnings ratio

-

Dividend yield

0.00%

Volume

150.52K

High today

$33.03

Low today

$31.82

Open price

$32.32

52-week high

$41.61

52-week low

$28.14

Ready to start your investing journey with Stake?

Open an account

HRMY FAQs

  1. Find the right investing platform for you. To buy HRMY shares in Australia, you’ll need to open an account with an investing platform that offers the security. Try Stake, you can sign up in minutes.
  2. Fund your brokerage account. Once you are set up you can deposit into your account with different payment methods.
  3. Search for HRMY or Harmony Biosciences Holdings Inc. Find the stock by using the search function and go to the HRMY page.
  4. Place an order to buy HRMY. Press the ‘Buy’ button and choose an order type to place your trade. Depending on the order type, the trade will go through straight away or when a price target is hit.
  5. Monitor your portfolio. You’ve now purchased some HRMY shares. Stay on top of your portfolio and monitor its performance. You may be eligible for dividends and shareholder voting rights that affect your stock.

The ticker symbol for Harmony Biosciences Holdings Inc is HRMY.

One share of HRMY is valued at $32.04 as of 12 December 2024.

As of 12 December 2024 Harmony Biosciences Holdings Inc has a market cap of $1.84B.

The Price to Earnings ratio of HRMY is 15.28.

The Earnings Per Share of HRMY is $2.11.

The Harmony Biosciences Holdings Inc 52-week high stock price is $41.61.

The Harmony Biosciences Holdings Inc 52-week low stock price is $28.14.

Yes, the Stake investing platform allows you to buy HRMY shares and over 12,000 more stocks and ETFs across the ASX and Wall St.

This is not financial product advice nor a recommendation to invest in the securities listed. Past performance is not a reliable indicator of future performance. As always, do your own research and consider seeking financial, legal and taxation advice before investing. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.

Invest in HRMY
on Stake

Buy HRMY from US$3 brokerage

Invest in 9,500+ U.S. stocks and ETFs

Own a slice of HRMY from only US$10 with fractional shares

Get started
Canstar award phone
Stock shown for demonstrative purposes only. US$3 brokerage up to US$30,000.
HRMY related stocks

Stake logo
Over 7,000 5-star reviews
App Store logoGoogle Play logo

Subscribe to our free newsletters

By subscribing, you agree to our Privacy Policy.

Stakeshop Pty Ltd, trading as Stake, ACN 610 105 505, is an authorised representative (Authorised Representative No. 1241398) of Stakeshop AFSL Pty Ltd (Australian Financial Services Licence no. 548196). Stake SMSF Pty Ltd ACN 648 283 532 (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. For more information about SMSFs, see our SMSF Risks page. The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services GuideTerms & ConditionsPrivacy Policy and Disclaimers before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

Copyright © 2024 Stake. All rights reserved.